Q3 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Innovation: Pipeline overview
Appendix
Innovation: Clinical trials
References
Abbreviations
Confident in future growth driven by our strength and depth in
cardiovascular, immunology, neuroscience...
Selected assets, nearly all with exclusivity into 2030+
Cardiovascular
Immunology
Asset
Indication
Peak Sales
Next Milestone/ Status
Submission
Asset
Indication
Peak Sales Next Milestone/ Status
Submission
Leqvio®
CVRR-LDLC
Ph3 ORION-4 and VICTORION-2-
PREVENT ongoing
2026+
CosentyxⓇ
Submitted in US
HS
Primary prevention initiation
GCA
Iptacopan1 IgAN
Ph3 APPLAUSE-IgAN ongoing
20232
Pelacarsen
Neuroscience
C3G
iMN
CVRR-Lp(a)
Ph3 APPEAR-C3G ongoing
Ph2b ongoing
Lupus Nephritis
Ph3 GCAPTAIN ongoing
Ph3 SELUNE ongoing
2025
2026+
Ph3 Lp(a)HORIZON ongoing
2023
2026+
2025
Ligelizumab
Remibrutinib¹
Food allergy
Ph3 ongoing
2025
CSU
Ph3 REMIX-1 and -2 ongoing
2024
Asset
Indication
Peak Sales
Next Milestone/ Status
Submission
lanalumab
Other indications being explored
Sjögren's
ZolgensmaⓇ
SMA IT
Ph3 STEER ongoing
2025
SLE
Ph3 NEPTUNUS-1 and -2 started
Ph2a ongoing
2026+
2026+
Autoimmune hepatitis
Ph2b AMBER ongoing
2026+
Branaplam
Huntington's disease
Ph2b VIBRANT-HD ongoing
2026+
Remibrutinib¹ Multiple sclerosis
Ph3 REMODEL-1 and -2 ongoing
2026+
Iscalimab
Lupus Nephritis
Sjögren's
Ph3 SIRIUS-LN started
2026+
DLX313
Parkinson's disease
Ph2 ongoing
2026+
HS
(UCB0599)
Ph2b TWINSS ongoing
Ph2a ongoing
2026+
2026+
Unprobabilized peak sales (USD): <1bn ..1-2bn
... >2bn
'Bold Bets'
LNA043 (osteoarthritis: Ph2b ONWARDS ongoing), SAF312 (COSP: Ph2b ongoing)
1. Peak sales potential based on all studied indications. 2. Based on 9 months UPCR readout (US accelerated approval)
34 Investor Relations | Q3 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation